Find Teverelix Trifluoroacetate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: J5oul9shw5, D-alaninamide, n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-(aminocarbonyl)-d-lysyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl-, bis(trifluoroacetate) (salt), Unii-j5oul9shw5, 244792-29-8, 500717-24-8
Molecular Formula
C78H102ClF6N15O18
Molecular Weight
1687.2  g/mol
InChI Key
XCOCXBFSPCRONC-SAECRDNQSA-N
FDA UNII
J5OUL9SHW5

Teverelix Trifluoroacetate
Teverelix Trifluoroacetate is the trifluoroacetate (TFA) salt form of teverelix, a synthetic decapeptide and antagonist of the naturally occurring gonadotropin-releasing hormone (GnRH), with potential hormone production inhibitory and antineoplastic activities. Upon administration, teverelix directly competes with GnRH for receptor binding in the anterior pituitary gland, thereby inhibiting GnRH receptor signaling. This inhibits the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In females, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases.
1 2D Structure

Teverelix Trifluoroacetate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(carbamoylamino)hexanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid
2.1.2 InChI
InChI=1S/C74H100ClN15O14.2C2HF3O2/c1-43(2)35-57(66(96)84-56(19-10-11-32-79-44(3)4)73(103)90-34-14-20-63(90)72(102)81-45(5)64(76)94)85-65(95)55(18-9-12-33-80-74(77)104)83-68(98)59(38-48-24-29-54(93)30-25-48)88-71(101)62(42-91)89-70(100)61(40-50-15-13-31-78-41-50)87-69(99)60(37-47-22-27-53(75)28-23-47)86-67(97)58(82-46(6)92)39-49-21-26-51-16-7-8-17-52(51)36-49;2*3-2(4,5)1(6)7/h7-8,13,15-17,21-31,36,41,43-45,55-63,79,91,93H,9-12,14,18-20,32-35,37-40,42H2,1-6H3,(H2,76,94)(H,81,102)(H,82,92)(H,83,98)(H,84,96)(H,85,95)(H,86,97)(H,87,99)(H,88,101)(H,89,100)(H3,77,80,104);2*(H,6,7)/t45-,55-,56+,57+,58-,59+,60-,61-,62+,63+;;/m1../s1
2.1.3 InChI Key
XCOCXBFSPCRONC-SAECRDNQSA-N
2.1.4 Canonical SMILES
CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O
2.1.5 Isomeric SMILES
C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O
2.2 Other Identifiers
2.2.1 UNII
J5OUL9SHW5
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. J5oul9shw5

2. D-alaninamide, N-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-(aminocarbonyl)-d-lysyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl-, Bis(trifluoroacetate) (salt)

3. Unii-j5oul9shw5

4. 244792-29-8

5. 500717-24-8

2.4 Create Date
2020-01-23
3 Chemical and Physical Properties
Molecular Weight 1687.2 g/mol
Molecular Formula C78H102ClF6N15O18
Hydrogen Bond Donor Count17
Hydrogen Bond Acceptor Count26
Rotatable Bond Count41
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area520
Heavy Atom Count118
Formal Charge0
Complexity2890
Isotope Atom Count0
Defined Atom Stereocenter Count10
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3

ABOUT THIS PAGE

Looking for 500717-24-8 / Teverelix Trifluoroacetate API manufacturers, exporters & distributors?

Teverelix Trifluoroacetate manufacturers, exporters & distributors 1

38

PharmaCompass offers a list of Teverelix Trifluoroacetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Teverelix Trifluoroacetate manufacturer or Teverelix Trifluoroacetate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Teverelix Trifluoroacetate manufacturer or Teverelix Trifluoroacetate supplier.

PharmaCompass also assists you with knowing the Teverelix Trifluoroacetate API Price utilized in the formulation of products. Teverelix Trifluoroacetate API Price is not always fixed or binding as the Teverelix Trifluoroacetate Price is obtained through a variety of data sources. The Teverelix Trifluoroacetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Teverelix Trifluoroacetate

Synonyms

J5oul9shw5, D-alaninamide, n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-(aminocarbonyl)-d-lysyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl-, bis(trifluoroacetate) (salt), Unii-j5oul9shw5, 244792-29-8, 500717-24-8

Cas Number

500717-24-8

Unique Ingredient Identifier (UNII)

J5OUL9SHW5

About Teverelix Trifluoroacetate

Teverelix Trifluoroacetate is the trifluoroacetate (TFA) salt form of teverelix, a synthetic decapeptide and antagonist of the naturally occurring gonadotropin-releasing hormone (GnRH), with potential hormone production inhibitory and antineoplastic activities. Upon administration, teverelix directly competes with GnRH for receptor binding in the anterior pituitary gland, thereby inhibiting GnRH receptor signaling. This inhibits the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In females, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases.

Teverelix Trifluoroacetate Manufacturers

A Teverelix Trifluoroacetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Teverelix Trifluoroacetate, including repackagers and relabelers. The FDA regulates Teverelix Trifluoroacetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Teverelix Trifluoroacetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Teverelix Trifluoroacetate Suppliers

A Teverelix Trifluoroacetate supplier is an individual or a company that provides Teverelix Trifluoroacetate active pharmaceutical ingredient (API) or Teverelix Trifluoroacetate finished formulations upon request. The Teverelix Trifluoroacetate suppliers may include Teverelix Trifluoroacetate API manufacturers, exporters, distributors and traders.

Teverelix Trifluoroacetate GMP

Teverelix Trifluoroacetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Teverelix Trifluoroacetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Teverelix Trifluoroacetate GMP manufacturer or Teverelix Trifluoroacetate GMP API supplier for your needs.

Teverelix Trifluoroacetate CoA

A Teverelix Trifluoroacetate CoA (Certificate of Analysis) is a formal document that attests to Teverelix Trifluoroacetate's compliance with Teverelix Trifluoroacetate specifications and serves as a tool for batch-level quality control.

Teverelix Trifluoroacetate CoA mostly includes findings from lab analyses of a specific batch. For each Teverelix Trifluoroacetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Teverelix Trifluoroacetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Teverelix Trifluoroacetate EP), Teverelix Trifluoroacetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Teverelix Trifluoroacetate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty